$12.62
2.70% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$12.97
-2.51 16.21% 1M
-6.47 33.28% 6M
-0.25 1.89% YTD
-10.32 44.31% 1Y
-6.15 32.17% 3Y
+3.23 33.16% 5Y
+0.96 7.99% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.96 7.99%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Market capitalization $1.12b
Enterprise Value $888.60m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 37.53
P/S ratio (TTM) P/S ratio 47.12
P/B ratio (TTM) P/B ratio 3.86
Revenue (TTM) Revenue $23.68m
EBIT (operating result TTM) EBIT $-339.67m
Free Cash Flow (TTM) Free Cash Flow $-274.90m
Cash position $572.88m
EPS (TTM) EPS $-3.73
P/E forward negative
P/S forward 12.55
EV/Sales forward 9.99
Short interest 22.06%
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
93%
Hold
7%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
24 24
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 121 121
81% 81%
510%
- Research and Development Expense 242 242
48% 48%
1,020%
-340 -340
48% 48%
-1,434%
- Depreciation and Amortization 0.01 0.01
96% 96%
0%
EBIT (Operating Income) EBIT -340 -340
48% 48%
-1,434%
Net Profit -319 -319
52% 52%
-1,346%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
one day ago
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum ...
Neutral
GlobeNewsWire
29 days ago
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will ves...
Neutral
Seeking Alpha
about one month ago
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gallagher - President and Head of R&D Keith Goldan - CFO Anjali Ganguli - CSO Conference Call Participants Anupam Rama - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman...
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 270
Founded 2005
Website www.syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today